Cosmos Health in Talks for €25M EIB Financing, Eliminates 38% Warrant Overhang with No Dilution
COSM is trading near its 52-week low of $0.246 (3.5% above the low) on elevated volume (3.0× avg).
Summary
Cosmos Health announced it is in discussions with the European Investment Bank for up to €25 million in financing for its R&D, a sum significantly larger than its current market capitalization. The company also eliminated 38% of its outstanding warrants without dilution, simplifying its capital structure. This follows a recent 10-Q filing that included a going concern warning and widened losses, making the potential financing a critical development. The EIB discussions build on an advisory agreement announced on May 14th, now specifying a substantial potential funding amount. The company also highlighted a $4.5 million reduction in liabilities and a $1.4 million increase in stockholders' equity in Q1 2026. The outcome of the EIB financing discussions will be critical.
At the time of this announcement, COSM was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.1M. The 52-week trading range was $0.25 to $1.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.